Prime Medicine, Inc. 8-K

What Happened
Prime Medicine, Inc. announced its financial results and business highlights for the quarter ended March 31, 2026 by issuing a press release on May 7, 2026. The company furnished that press release as Exhibit 99.1 to a Current Report on Form 8‑K (Item 2.02), which was signed by CEO Allan Reine. The 8‑K notifies investors that the company reported its quarterly results, with the detailed figures provided in the press release.

Key Details

• Filing date: May 7, 2026 (Form 8‑K filed under Item 2.02: Results of Operations and Financial Condition).
• Period covered: Quarter ended March 31, 2026 (Q1 2026).
• Disclosure: Press release announcing results and business highlights furnished as Exhibit 99.1 to the 8‑K.
• Signature: Report signed by Allan Reine, Chief Executive Officer of Prime Medicine.

Why It Matters
This 8‑K signals that Prime Medicine has released its quarterly earnings and business update—information investors use to assess recent revenue, expenses, cash runway, pipeline progress, and near‑term outlook. The Form 8‑K itself references the press release rather than embedding detailed financial tables; investors should read the Exhibit 99.1 press release (and upcoming 10‑Q if available) for specific revenue, earnings, guidance, and operational details that could affect the stock.